Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

Study Background and Research Question

The renin-angiotensin system (RAS) is a fundamental regulator of cardiovascular and renal physiology, primarily known for its role in blood pressure and fluid homeostasis. Angiotensin peptides, derived from the enzymatic processing of angiotensinogen, include a spectrum of biologically active fragments, such as Angiotensin II (1–8), Angiotensin (1–7), and the H2N-Ile-His-Pro-OH peptide (Angiotensin 1/2 (5-7)). Traditionally, these peptides have been studied for their vasoconstrictor or vasodilatory effects and their contributions to hypertension and related pathologies.

The emergence of SARS-CoV-2 and the subsequent COVID-19 pandemic spotlighted the RAS pathway, as the virus’s spike protein exploits the angiotensin-converting enzyme 2 (ACE2) receptor for cell entry. Yet, alternative receptors such as AXL and neuropilin-1 (NRP1) may also facilitate infection, particularly in tissues with low ACE2 expression. The reference study (Oliveira et al., 2025) sought to determine how naturally occurring angiotensin peptides influence the binding of the SARS-CoV-2 spike protein to these host cell receptors, with a focus on AXL.

Key Innovation from the Reference Study

The central innovation of the Oliveira et al. study is the demonstration that not only canonical angiotensin peptides but also shorter, naturally occurring fragments—including Angiotensin 1/2 (5-7)—potently enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. This finding extends the mechanistic understanding of viral entry beyond ACE2-dependent pathways and highlights new intersections between cardiovascular peptide signaling and viral infectivity. Notably, the study reveals that sequence truncations at the N-terminus of angiotensin peptides result in greater spike–AXL binding enhancement, implicating specific peptide motifs as modulators of viral-receptor interactions.

Methods and Experimental Design Insights

The study employed antibody-based binding assays to quantify the interaction between recombinant SARS-CoV-2 spike protein and three host receptors: ACE2, NRP1, and AXL. A panel of angiotensin peptides—including full-length Angiotensin I (1–10), Angiotensin II (1–8), Angiotensin (1–7), and truncated forms such as Angiotensin (2–8), Angiotensin (3–8), Angiotensin (2–7), and Angiotensin (5–7)—was systematically tested for its effect on spike–receptor binding. Additionally, peptide modifications (e.g., substitution or phosphorylation at position 4) were explored to probe structure–activity relationships.

Quantitative binding measurements were made using ELISA-based assays, allowing for the direct comparison of peptide effects on spike–receptor interactions across multiple conditions. This approach enabled the identification of sequence features and chemical modifications that modulate the enhancement of viral binding.

Core Findings and Why They Matter

The study’s results revealed several key points:

• Angiotensin II (1–8) increased spike–AXL binding by approximately two-fold, but had no significant effect on ACE2 or NRP1 binding.
• Shorter C-terminal fragments—such as Angiotensin (1–7) and Angiotensin (1–6)—also enhanced spike–AXL binding with similar potency to Angiotensin II.
• N-terminal truncations (e.g., Angiotensin III (2–8), Angiotensin IV (3–8), Angiotensin (5–7)) produced even greater enhancement, with Angiotensin IV yielding a 2.7-fold increase in spike–AXL binding.
• Specific residue modifications at position 4 (tyrosine substitution or phosphorylation) further amplified spike–AXL binding, underscoring the mechanistic importance of this motif.
• Some truncated peptides (notably Angiotensin IV) also enhanced binding to ACE2 and NRP1, suggesting a broader effect on viral entry pathways.

Collectively, these findings demonstrate that the H2N-Ile-His-Pro-OH peptide (Angiotensin 1/2 (5-7)), a well-established vasoconstrictor and blood pressure regulation peptide, can modulate viral protein–receptor interactions. This link provides a mechanistic rationale for observed clinical associations between RAS dysregulation and COVID-19 severity, as circulating angiotensin fragments may impact viral tropism and infectivity, according to the reference study.

Comparison with Existing Internal Articles

Several recent reviews and research highlights have contextualized these findings within broader RAS and viral pathogenesis frameworks. For example, "Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding" corroborates that truncated angiotensin peptides facilitate viral spike–AXL interactions, reinforcing the reference study’s mechanistic insights. Similarly, another internal article emphasizes the experimental opportunity this presents for both cardiovascular and infectious disease research workflows.

From a peptide-centric perspective, "Angiotensin 1/2 (5-7): Atomic Profile of a Potent Vasoconstrictor" and its companion articles detail the atomic structure and validated biological activities of the H2N-Ile-His-Pro-OH peptide, supporting its selection as a model peptide for dissecting both blood pressure regulation and viral pathogenesis mechanisms.

Limitations and Transferability

While the study provides robust biochemical evidence for peptide-mediated enhancement of spike–AXL binding, several limitations warrant consideration. The results were derived from in vitro binding assays using recombinant proteins, which may not fully capture the complexity of in vivo peptide concentrations, receptor distributions, and proteolytic processing. The physiological relevance of these enhancements—such as their impact on viral infectivity in the context of circulating peptide levels—remains to be elucidated in cellular or animal models. Additionally, while the study implicates specific peptide motifs as enhancers, it does not directly address downstream consequences for infection efficiency or disease progression.

Why this cross-domain matters, maturity, and limitations

The observed enhancement of viral spike–host receptor interactions by vasoconstrictor peptide hormones such as Angiotensin 1/2 (5-7) bridges cardiovascular and infectious disease research domains. This cross-domain insight is mature at the biochemical and receptor-binding level, as demonstrated in the reference study, but downstream consequences and therapeutic implications remain at an exploratory stage. As such, these findings empower hypothesis generation for translational studies without immediately altering clinical practice.

Protocol Parameters

• Peptide binding assays: Utilize ELISA-based protocols to quantify spike protein interaction with host receptors (AXL, ACE2, NRP1) in the presence of candidate angiotensin peptides.
• Peptide concentrations: The reference study tested physiologically relevant concentrations (typically micromolar range); titration is recommended to determine dose–response relationships.
• Sequence variants: Compare full-length and truncated peptides (e.g., Angiotensin II (1–8), Angiotensin (1–7), Angiotensin (5–7)) to map structure–function effects.
• Modification analysis: Explore residue substitutions or phosphorylation to probe structure–activity relationships at key positions (e.g., Tyr4).
• Solubility and handling: The product information reports high solubility for Angiotensin 1/2 (5-7) in DMSO, ethanol, and water, facilitating preparation for in vitro assays.

Research Support Resources

Researchers interested in further dissecting renin-angiotensin system signaling or modeling hypertension and viral pathogenesis can leverage high-purity Angiotensin 1/2 (5-7) (SKU A1049) from APExBIO. The H2N-Ile-His-Pro-OH peptide is supplied with validated purity and solubility to support diverse assay formats, as detailed in the product dossier. Careful attention to peptide handling and experimental design, as outlined above, will maximize result interpretability for both cardiovascular and viral research workflows.